Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.72M Buy
7,923
+491
+7% +$109K 0.58% 39
2025
Q4
$1.7M Sell
7,432
-50
-0.7% -$11.4K 0.57% 36
2025
Q3
$1.73M Hold
7,482
0.61% 35
2025
Q2
$1.39M Hold
7,482
0.49% 49
2025
Q1
$1.57M Buy
7,482
+183
+3% +$35.6K 0.58% 43
2024
Q4
$1.3M Buy
7,299
+38
+0.5% +$6.99K 0.47% 51
2024
Q3
$1.43M Hold
7,261
0.51% 46
2024
Q2
$1.25M Hold
7,261
0.47% 48
2024
Q1
$1.32M Sell
7,261
-12
-0.2% -$2.07K 0.48% 48
2023
Q4
$1.13M Buy
7,273
+53
+0.7% +$7.73K 0.44% 54
2023
Q3
$1.08M Sell
7,220
-500
-6% -$73.4K 0.48% 55
2023
Q2
$1.04M Buy
7,720
+175
+2% +$25.7K 0.44% 61
2023
Q1
$1.2M Sell
7,545
-375
-5% -$57.3K 0.54% 48
2022
Q4
$1.28M Buy
7,920
+110
+1% +$16.9K 0.59% 43
2022
Q3
$1.05M Hold
7,810
0.57% 45
2022
Q2
$1.2M Buy
7,810
+569
+8% +$86.9K 0.62% 42
2022
Q1
$1.17M Buy
7,241
+992
+16% +$144K 0.55% 48
2021
Q4
$846K Buy
6,249
+177
+3% +$20.9K 0.39% 70
2021
Q3
$655K Hold
6,072
0.33% 78
2021
Q2
$684K Hold
6,072
0.34% 76
2021
Q1
$657K Buy
6,072
+50
+0.8% +$5.35K 0.36% 73
2020
Q4
$645K Sell
6,022
-75
-1% -$7.21K 0.37% 74
2020
Q3
$534K Sell
6,097
-207
-3% -$19.5K 0.35% 79
2020
Q2
$619K Sell
6,304
-76
-1% -$6.69K 0.42% 70
2020
Q1
$486K Buy
6,380
+550
+9% +$46.8K 0.38% 77
2019
Q4
$516K Sell
5,830
-100
-2% -$8.3K 0.31% 78
2019
Q3
$449K Buy
5,930
+252
+4% +$17.3K 0.29% 82
2019
Q2
$413K Sell
5,678
-62
-1% -$4.87K 0.29% 83
2019
Q1
$463K Sell
5,740
-18
-0.3% -$1.47K 0.34% 78
2018
Q4
$531K Buy
5,758
+11
+0.2% +$967 0.44% 65
2018
Q3
$544K Sell
5,747
-180
-3% -$17.1K 0.38% 75
2018
Q2
$549K Buy
5,927
+309
+6% +$30.2K 0.5% 59
2018
Q1
$531K Buy
5,618
+10
+0.2% +$1.1K 0.48% 60
2017
Q4
$542K Sell
5,608
-100
-2% -$9.43K 0.48% 60
2017
Q3
$507K Sell
5,708
-130
-2% -$9.9K 0.48% 60
2017
Q2
$423K Sell
5,838
-100
-2% -$6.72K 0.41% 66
2017
Q1
$387K Sell
5,938
-50
-0.8% -$3.14K 0.37% 68
2016
Q4
$375K Buy
+5,988
New +$366K 0.37% 69

Other funds holding ABBV

LCNB Corp's ABBV Position: Q1 2026 in Review

LCNB Corp increased its AbbVie (ABBV) stake by 6.6% in Q1 2026, buying an estimated $109K and bringing the position to 7,923 shares worth $1.72M. The position accounts for 0.58% of the portfolio, ranked #39.

LCNB Corp first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. The position peaked at $1.73M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • LCNB Corp held 7,923 shares of AbbVie worth $1.72M as of Q1 2026.
  • LCNB Corp bought 491 AbbVie shares in Q1 2026, an estimated $109K.
  • AbbVie made up 0.58% of LCNB Corp's portfolio in Q1 2026, its #39 holding.
  • LCNB Corp first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
  • LCNB Corp's AbbVie position peaked at $1.73M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on LCNB Corp's 13F filing for Q1 2026, filed 11 May 2026.